190 related articles for article (PubMed ID: 37166793)
1. Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy.
Mouabbi JA; Singareeka Raghavendra A; Bassett RL; Hassan A; Tripathy D; Layman RM
JAMA Netw Open; 2023 May; 6(5):e2313017. PubMed ID: 37166793
[TBL] [Abstract][Full Text] [Related]
2. Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
Carausu M; Carton M; Diéras V; Petit T; Guiu S; Gonçalves A; Augereau P; Ferrero JM; Levy C; Ung M; Desmoulins I; Debled M; Bachelot T; Pistilli B; Frenel JS; Mailliez A; Chevrot M; Cabel L
JAMA Netw Open; 2022 Dec; 5(12):e2247154. PubMed ID: 36520434
[TBL] [Abstract][Full Text] [Related]
3. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
5. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
[TBL] [Abstract][Full Text] [Related]
6. Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
Cook MM; Al Rabadi L; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
Oncologist; 2021 Feb; 26(2):101-106. PubMed ID: 33230905
[TBL] [Abstract][Full Text] [Related]
7. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
8. Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies.
Mouabbi JA; Raghavendra AS; Bassett RL; Hassan A; Tripathy D; Layman RM
NPJ Breast Cancer; 2022 Dec; 8(1):131. PubMed ID: 36539444
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
[TBL] [Abstract][Full Text] [Related]
10. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Conte P; Lu Y; Barriga S; Hurt K; Frenzel M; Johnston S; Llombart-Cussac A
JAMA Oncol; 2020 Jan; 6(1):116-124. PubMed ID: 31563959
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
[TBL] [Abstract][Full Text] [Related]
13. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
[TBL] [Abstract][Full Text] [Related]
14. A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience.
Sarfraz H; Bari S; Whiting J; Sur M; Mo Q; Armitage M; Costa RLB
Oncology; 2024; 102(5):414-424. PubMed ID: 38011835
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
[TBL] [Abstract][Full Text] [Related]
16. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
Nagaraj G; Ma CX
Adv Ther; 2021 Jan; 38(1):109-136. PubMed ID: 33190190
[TBL] [Abstract][Full Text] [Related]
17. Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.
Frenel JS; Zeghondy J; Guérin-Charbonnel C; Mailliez A; Volant E; Poumeaud F; Patsouris A; Arnedos M; Bailleux C; Cabal J; Galland L; de Nonneville A; Guiu S; Dalenc F; Pistilli B; Bachelot T; Pierga JY; Le Du F; Bocquet F; Larrouquere L; Loirat D
JAMA Netw Open; 2024 Apr; 7(4):e244435. PubMed ID: 38568692
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs.
Iwamoto T; Fujisawa T; Shien T; Araki K; Sakamaki K; Sangai T; Kikawa Y; Takao S; Nishimura R; Takahashi M; Aihara T; Mukai H; Taira N
Breast Cancer; 2020 Sep; 27(5):973-981. PubMed ID: 32394413
[TBL] [Abstract][Full Text] [Related]
19. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021.
Jaber Chehayeb R; Hood A; Wang X; Miksad R; Schellhorn Mougalian S; Lustberg MB; Wang SY; Greenup RA; Pusztai L; Kunst N
JAMA Netw Open; 2022 Nov; 5(11):e2244204. PubMed ID: 36445704
[TBL] [Abstract][Full Text] [Related]
20. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
